Lilly, Boehringer Win U.S. Approval for Type 2 Diabetes Drug

Eli Lilly & Co. (LLY) and Boehringer Ingelheim GmbH won U.S. approval of a new drug to improve blood glucose control in people with Type 2 diabetes.

The drug, linagliptin, was shown to be safe and effective in eight clinical studies involving about 3,800 patients with Type 2 diabetes, the most common form of the disease, the Food and Drug Administration said today in a statement.

To contact the reporter on this story: Molly Peterson in Washington at mpeterson9@bloomberg.net

To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.